Trial Profile
Phase II study of concurrent carboplatin, pemetrexed, and radiotherapy for limited stage of small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 08 Apr 2022 This trial has been completed in Spain (End Date: 20 Dec 2008), according to European Clinical Trials Database record.
- 17 Dec 2009 Actual end date (October 2008) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual patient number (4) added as reported by ClinicalTrials.gov.